Maheep Sangha

Maheep Sangha

Auto-generated profile, based on publicly available information

Maheep Sangha

Department of Medicine, Lenox Hill Hospital, Northwell Health , New York, New York , USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2021 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
MSMaheep Sangha
Maheep Sangha
IRIsabel Roitman
Isabel Roitman
KSKeith Sultan
Keith Sultan
ASArun Swaminath
Arun Swaminath

1 June 2020 in Gastroenterology
Verified
Journal Article
Closed access
MSMaheep Sangha
Maheep Sangha
CKColleen R. Kelly
Colleen R. Kelly
LRLisa Rauschert
Lisa Rauschert

1 October 2021 in Crohn's & Colitis 360
Verified
Journal Article
Open access
PDF file
JSJonathan M Schachne
Jonathan M Schachne
LDLaura L Durbin
Laura L Durbin
CLCorey R Lacher
Corey R Lacher
MSMaheep Sangha
Maheep Sangha
AMAnjali Mone
Anjali Mone
ASArun Swaminath
Arun Swaminath
Background: Infliximab is a weight-based prescription for multiple autoimmune diseases and is dispensed only in single-use, 100mg vials. We aim to compute the quantity of infliximab waste at our site and in an ideal world where weight-based prescribing practices are followed. We estimate hypothetical waste reduction and cost-savings if a smaller vial is dispensed. We also surveyed gastroenterologists to study prescription rounding practices for infliximab. Methods: A pre-existing registry of 426 inflammatory bowel disease patients identified 112 individuals who had received a total of 1003 infliximab administrations from December 2013 to May 2019. We calculated infliximab wastage per administration for the real world and an ideal (weight-based) world. Analysis of potential waste reduction and cost-savings was computed with the hypothetical creation of 50 and 25mg vials. Infliximab-prescribing gastroenterologists completed an online survey, determining reasons for rounding of weight-based prescription, rounding practices, and biosimilar use. Results: At our site, the total value of infliximab wasted was between $112738.08 and $243209.50. Utilizing 50 and 25mg vials would reduce this waste by 92.2% and 99.4%, respectively. If prescriber guidelines were followed precisely, the total value of waste was between $132781.08 and $286448.19. Utilizing 50 and 25mg vials would reduce waste by 50.39% and 75.34%, respectively. The physician survey revealed that 68.1% rounded doses while only 31.9% prescribed exact weight-based doses. Conclusions: Infliximab-prescribing gastroenterologists considered reducing drug waste as a common reason in their rounding practices. Our analysis demonstrates significant waste reduction and cost-savings are possible with the introduction of 50 and 25mg vials.

2 May 2016 in British Journal of Hospital Medicine
Verified
Journal Article
Closed access
MSMaheep Sangha
Maheep Sangha
AAAlok Arora
Alok Arora
KSKeith Shulman
Keith Shulman

21 May 2020 in Case Reports in Internal Medicine
Verified
Journal Article
Open access
PDF file
MSMaheep Singh Sangha
Maheep Singh Sangha
AAAakash Aggarwal
Aakash Aggarwal
JSJapmehr Sandhu
Japmehr Sandhu
Spur cells are reportedly linked to advanced end-stage liver diseases and may lead to accelerated hemolysis. In this case report, we discuss one of these rare instances when a 45-year-old female with decompensated cirrhosis was admitted for severe anemia. Extensive workup revealed non-immune hemolysis secondary to spur cell formation. Orthotopic liver transplantation remains the only treatment of choice for reversal of spur cell anemia. Alternatively, multidrug therapy has also been explored, including usage of bile acid sequestrants; however, success is rare.